Quest Laboratories Ltd
Incorporated in 1998, Quest Laboratories Ltd is a pharmaceutical manufacturer specializing in diverse therapeutic segments[1]
- Market Cap ₹ 154 Cr.
- Current Price ₹ 94.2
- High / Low ₹ 160 / 75.2
- Stock P/E 11.4
- Book Value ₹ 49.9
- Dividend Yield 0.00 %
- ROCE 26.9 %
- ROE 24.6 %
- Face Value ₹ 10.0
Pros
- Company has a good return on equity (ROE) track record: 3 Years ROE 32.0%
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Working capital days have increased from 153 days to 346 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| 30 | 59 | 62 | 83 | 104 | |
| 29 | 53 | 54 | 67 | 88 | |
| Operating Profit | 1 | 6 | 8 | 16 | 16 |
| OPM % | 5% | 11% | 13% | 19% | 15% |
| 0 | 0 | 0 | 0 | 4 | |
| Interest | 0 | 0 | 1 | 1 | 1 |
| Depreciation | 0 | 0 | 1 | 1 | 1 |
| Profit before tax | 1 | 6 | 7 | 14 | 19 |
| Tax % | 18% | 29% | 28% | 30% | 27% |
| 1 | 4 | 5 | 10 | 14 | |
| EPS in Rs | 8.45 | 8.28 | |||
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 20% |
| TTM: | 26% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 49% |
| TTM: | 34% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -34% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 32% |
| Last Year: | 25% |
Balance Sheet
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 12 | 16 |
| Reserves | 5 | 9 | 14 | 17 | 65 |
| 3 | 3 | 4 | 5 | 30 | |
| 9 | 22 | 28 | 26 | 10 | |
| Total Liabilities | 18 | 35 | 47 | 59 | 122 |
| 6 | 7 | 10 | 10 | 12 | |
| CWIP | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 52 |
| 12 | 27 | 37 | 49 | 58 | |
| Total Assets | 18 | 35 | 47 | 59 | 122 |
Cash Flows
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| 1 | 3 | 4 | 3 | -23 | |
| -1 | -2 | -4 | -5 | -44 | |
| 0 | -0 | 0 | 2 | 67 | |
| Net Cash Flow | -0 | 1 | 0 | 0 | -0 |
Ratios
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Debtor Days | 110 | 135 | 118 | 104 | 105 |
| Inventory Days | 12 | 9 | 97 | 113 | 99 |
| Days Payable | 119 | 140 | 215 | 137 | 26 |
| Cash Conversion Cycle | 3 | 4 | 1 | 79 | 178 |
| Working Capital Days | 31 | 25 | 40 | 74 | 346 |
| ROCE % | 55% | 47% | 58% | 27% |
Documents
Announcements
-
Trading Window
28 June 2025 - Trading window closed from July 1, 2025 till 48 hours post Q1 FY26 results announcement.
-
Trading Window-XBRL
28 June 2025 - QUEST LABORATORIES LIMITED has informed about Closure of Trading Window
-
Updates
27 June 2025 - Shareholders approved appointment of new statutory auditor for FY 2024-25 via postal ballot.
-
Clarification - Financial Results
24 June 2025 - Exchange has sought clarification from Quest Laboratories Limited for the quarter ended 31-Mar-2025 with respect to Regulation 33 of the SEBI (LODR) Regulations, 2015. On …
-
Analysts/Institutional Investor Meet/Con. Call Updates
11 June 2025 - Analyst meeting scheduled on 16 June 2025; no unpublished price sensitive info to be shared.
Business Overview:[1][2]
a) QLL specializes in manufacturing a wide range of pharmaceutical formulations, including antibiotics, antimalarials, anti-inflammatories, respiratory medications,
diabetes treatments, and more.
b) Company also produces a wide range of ethical, generic, and over-the-counter (OTC) drugs in various forms, including tablets, liquids, oral powders, ORS, ointments, and external liquids.
c) Quest offers facilities for institutional supplies, domestic ethical products, PCD, Contract manufacturing, and export, with
a focus on a wide range of specialized formulations and molecules
d) The company has 800+ Licensed Formulations, 272+ Active Products, 25cr.+Order Book from Myanmar